الرَنَح

إعداد فريق مايو كلينك
28 أغسطس 2026
  1. NINDS ataxias and cerebellar or spinocerebellar degeneration information page. National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov/Disorders/All-Disorders/Ataxias-and-Cerebellar-or-Spinocerebellar-Degeneration-Information-Page. Accessed March 21, 2022.
  2. Todd PK. Overview of cerebellar ataxias in adults. https://www.uptodate.com/contents/search. Accessed March 21, 2022.
  3. Ataxia classification. National Ataxia Foundation. https://ataxia.org/fact-sheets/. Accessed March 21, 2022.
  4. Ataxia telangiectasia information page. National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov/Disorders/All-Disorders/Ataxia-Telangiectasia-Information-Page. Accessed March 21, 2022.
  5. AskMayoExpert. Cerebellar ataxia. Mayo Clinic; 2022.
  6. Ataxia fact sheet. National Ataxia Foundation. https://ataxia.org/fact-sheets/. Accessed March 21, 2022.
  7. What is ataxia? National Ataxia Foundation. https://ataxia.org/what-is-ataxia/. Accessed March 21, 2022.
  8. Lee A. Omaveloxolone: First approval. Drugs. 2023; doi:10.1007/s40265-023-01874-9.
  9. Cortese A, et al. Cerebellar ataxia, neuropathy and vestibular areflexia syndrome (CANVAS): Genetic and clinical aspects. Practical Neurology. 2022; doi:10.1136/practneurol-2020-002822.
  10. Takao H, et al. Acute cerebellar ataxia during acute COVID-19: A case series and review of the literature. Journal of Infection and Chemotherapy. 2023; doi:10.1016/j.jiac.2023.04.003.
  11. Skyclarys (prescribing information). Reata Pharmaceuticals; 2023. https://hcp.skyclarys.com/. Accessed Dec. 18, 2023.
  12. Coarelli G, et al. The inherited cerebellar ataxias: An update. Journal of Neurology. 2023; doi:10.1007/s00415-022-11383-6.
  13. Skyclarys (approval letter). New Drug Application 216718. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216718Orig1s000TOC.cfm. Accessed Dec. 12, 2023.
  14. Ferri FF. Ferri's Clinical Advisor 2024. Elsevier; 2024. https://www.clinicalkey.com. Accessed Dec. 12, 2023.
  15. Radmard S, et al. Evaluation of cerebellar ataxic patients. Neurologic Clinics. 2023; doi:10.1016/j.ncl.2022.05.002.
  16. Rosenthal LS. Neurodegenerative cerebellar ataxia. Continuum. 2022; doi:10.1212/CON.0000000000001180.
  17. Ropper AH, et al. Ataxia and disorders of cerebellar function. In: Adams and Victor's Principles of Neurology. 12th ed. McGraw Hill; 2023. https://accessmedicine.mhmedical.com. Accessed Dec. 12, 2023.
  18. Silva Andrade B, et al. Long-COVID and post-COVID health complications: An up-to-date review on clinical conditions and their possible molecular mechanisms. Viruses. 2021; doi:10.3390/v13040700.
  19. Payne RM. Cardiovascular research in Friedreich ataxia: Unmet needs and opportunities. JACC. 2022; doi:10.1016/j.jacbts.2022.04.005.
  20. Khan M, et al. The care and management of children and young people with ataxia telangiectasia provided by nurses and allied health professionals: A scoping review. Cerebellum. 2023; doi:10.1007/s12311-023-01555-z.
  21. Mitoma H, et al. Mechanisms of ethanol-induced cerebellar ataxia: Underpinnings of neuronal death in the cerebellum. International Journal of Environmental Research and Public Health. 2021; doi:10.3390/ijerph18168678.
  22. Opal P, et al. Autosomal dominant spinocerebellar ataxias. https://www.uptodate.com/contents/search. Accessed Dec. 17, 2023.
  23. Hassan A. Episodic ataxias: Primary and secondary etiologies, treatment and classification approaches. Tremor and Other Hyperkinetic Movements. 2023; doi:10.5334/tohm.747.